Related Experiment Video
Updated: Aug 7, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
[Peptic ulcer disease. Clinical evaluation in 2006]
1Klinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-v.-Guericke Universität, Leipziger Strasse 44, 39120 Magdeburg, Germany. peter.malfertheiner@medizin.uni-magdeburg.de
Peptic ulcer treatment now focuses on eradicating Helicobacter pylori infection, a major cause. Antibiotic resistance in H. pylori and nonsteroidal antirheumatic agent-induced ulcers are key challenges.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Pharmacology
Background:
- Peptic ulcer disease (PUD) management transformed with the identification of Helicobacter pylori as the primary cause.
- Chronic H. pylori infection is now the main target for PUD treatment.
- Nonsteroidal antirheumatic (NSAR) agent and acetylsalicylic acid-induced ulcers are increasingly significant.
Purpose of the Study:
- To review current strategies for peptic ulcer disease treatment.
- To highlight the challenges of H. pylori eradication and antibiotic resistance.
- To discuss the role of proton pump inhibitors in managing NSAR-induced ulcers.
Main Methods:
- Literature review of peptic ulcer disease treatment modalities.
- Analysis of H. pylori eradication regimens and antibiotic resistance patterns.
- Evaluation of proton pump inhibitor efficacy in preventing and healing NSAR-induced ulcers.
Main Results:
- H. pylori eradication is central to peptic ulcer treatment.
- Antibiotic resistance complicates H. pylori eradication.
- Proton pump inhibitors effectively prevent and treat NSAR-induced ulcers.
Conclusions:
- Effective peptic ulcer management hinges on addressing H. pylori infection and its resistance.
- Optimized acid suppression with proton pump inhibitors is crucial for NSAR-induced ulcers.
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Peptic Ulcer
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...